Quality of Life Changes in Patients with Alport Syndrome: Results from the ATHENA Study. Quality of Life Changes in Patients with Alport Syndrome: Results from the ATHENA Study Post navigation Previous: Anti-miR-17 therapy delays tumorigenesis in MYC-driven hepatocellular carcinoma (HCC)Next: Efficacy of RGLS4326 in Human Primary 3D-Cyst Cultures Derived from Autosomal Dominant Polycystic Kidney Disease (ADPKD) Donors
